Altiratinib ainhibitor of MET, TIE2, VEGFR2 and TRK kinases approved for glioblastoma multiforme

Curious to know if TRK kinases as the targets would evolve and resist this novel approach, I wanted to re-blog and get some views on this. This approval must be based on their inability to develop alternate pathways. Makes one hope that management of the inoperable glioblastoma multiforme is now within reach! Thank you for the article on Altiratinib!

That it targets four very active participants is exciting and scary. Is it often that such an approach could have long term effects?

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

RePress from Dr. Melvin Crasto’s New Drug Approval site shows synthesis of Altratinib, a new antitumor compound which inhibits angiogenesis, tumor growth, and invasion metastasis just approved for use in glioblastoma multiforme.

Source: Altiratinib

View original post

Advertisements

2 thoughts on “Altiratinib ainhibitor of MET, TIE2, VEGFR2 and TRK kinases approved for glioblastoma multiforme

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s